PARSE BIOSCIENCES EXPANDS ASIA PRESENCE VIA SPINCO BIOTECH PARTNERSHIP

KUALA LUMPUR, Nov 10 (Bernama) -- Parse Biosciences, a provider of accessible and scalable single cell sequencing solutions, announced an agreement with India-based Spinco Biotech to further extend its reach in Asia.

According to Parse Biosciences in a statement, this is its latest expansion in the Asia Pacific region following an agreement last year with Research Instruments Pte Ltd to distribute its products in Southeast Asia.

“We are seeing increased demand for Parse’s Evercode single cell sequencing solutions across Asia, and we believe our products are poised for widespread adoption in India, as well.

“By partnering with Spinco, we are enabling their research community a way to easily adopt the leading single cell sequencing technology,” said Parse Biosciences chief executive officer and co-founder, Alex Rosenberg.

Meanwhile, Spinco Biotech founder and chairman, Thyagarajan Srinivasan said Parse is an important pioneer in single cell sequencing, and researchers here will greatly benefit from its Evercode technology.

“We are thrilled to partner with Parse to introduce this state of the art technology to India’s biotech community,” he said.

The company’s agreement with Spinco Biotech will give researchers in India full access to its single cell portfolio, including Evercode Whole Transcriptome, Evercode TCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Capture, CRISPR Detect, and the Parse Biosciences data analysis solution.

The agreement is a continuation of Parse’s ongoing introduction of its products in key international markets, which are also currently available in North America, Europe, Australia, South Korea, Singapore and New Zealand.

-- BERNAMA